CMEOF (Creo Medical Group) PE Ratio: 14.29 (As of Jun. 28, 2026) — Near Median


CMEOF Creo Medical Group PLC CMEOF
53 GF Score
Price $0.20
GF Value $0.25
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group PE Ratio?

Creo Medical Group CMEOF 53 PE Ratio is 14.29 as of Jun. 28, 2026, which is 9% above its 10-year median of 13.13. GuruFocus rates CMEOF with a GF Score™ of 53/100 and a GF Value™ of $0.25. The stock has 6 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-28), Creo Medical Group's share price is $0.20. Creo Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01. Therefore, Creo Medical Group's PE Ratio for today is 14.29.

During the past 11 years, Creo Medical Group's highest PE Ratio was 17.75. The lowest was 10.15. And the median was 13.13.

Creo Medical Group's EPS (Diluted) for the six months ended in Dec. 2025 was $-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.

As of today (2026-06-28), Creo Medical Group's share price is $0.20. Creo Medical Group's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.12. Therefore, Creo Medical Group's PE Ratio without NRI ratio for today is At Loss.

Creo Medical Group's EPS without NRI for the six months ended in Dec. 2025 was $-0.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.12.

Creo Medical Group's EPS (Basic) for the six months ended in Dec. 2025 was $-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.

Back to Basics: PE Ratio


Creo Medical Group  (OTCPK:CMEOF) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Creo Medical Group PE Ratio Related Terms


Creo Medical Group PE Ratio Historical Data

* Premium members only.

The historical data trend for Creo Medical Group's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creo Medical Group PE Ratio Chart

Creo Medical Group Annual Data
Trend Feb15 Feb16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A 9.90

Creo Medical Group Semi-Annual Data
Feb15 Feb16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss 9.90

CMEOF vs ABT, SYK, MDT: PE Ratio Comparison

For the Medical Devices subindustry, Creo Medical Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Creo Medical Group PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where Creo Medical Group's PE Ratio falls into.


CMEOF
53GF Score
Creo Medical Group PLC CMEOF
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creo Medical Group PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Creo Medical Group's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.20/0.014
=14.29

Creo Medical Group's Share Price of today is $0.20.
For company reported semi-annually, Creo Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 14.29 mean?
Creo Medical Group (CMEOF) has a PE Ratio of 14.29 as of Jun. 28, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Creo Medical Group and its competitors. This is near median its historical median of 13.13. Over the past decade, Creo Medical Group's PE Ratio has ranged from 10.15 to 17.75.
Is Creo Medical Group's PE Ratio too high?
Creo Medical Group's current PE Ratio of 14.29 is near median its 10-year median of 13.13. Over the past 10 years, this metric has ranged from a low of 10.15 to a high of 17.75. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's PE Ratio compare to ABT and SYK?
Creo Medical Group's PE Ratio of 14.29 can be compared against companies in the Medical Devices & Instruments industry. Historically, Creo Medical Group's own PE Ratio has ranged from 10.15 to 17.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Devices & Instruments company?
A good PE Ratio depends on the Medical Devices & Instruments industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Creo Medical Group and its competitors. Creo Medical Group's current PE Ratio is 14.29, which is near median its own 10-year median of 13.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current PE Ratio of 14.29. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current PE Ratio is 14.29, which is near median its 10-year median of 13.13. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current PE Ratio is 14.29 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (CMEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.

Key valuation signals for CMEOF:

  • PE Ratio: 14.29 (near median its 10-year median of 13.13)
  • GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score

Get the complete analysis for CMEOF

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.25
GF Value